Is it true OCEAN done in September?

Quote
With the target lists full of no-sees and no volumes, this has to be the biggest waste of money any pharma company has ever spent on a contract. You have to think that AZ would finally come to their senses and see what a waste of money this team is, but then again... probably not.
 






Anonymous said:
It most likely depends on performance. How the OCEAN sales team does in generating new prescriptions will likely be the determinant. Time will tell.
Click to expand...

When the full impact of Lipitor generic hits, it will do to Crestor what generic Zocor did to Lipitor- sales will fall quickly and never go back up. It is the law of the Managed care jungle. Generic Atorva will erode market share on Crestor. There is no therapeutic advantage with Crestor vs generic Atorva. Just watch the numbers slide- trust me it will happen. Pfizer is working to keep market share and giving it away with the 4 dollar copay card.
 






so leave a job that pays 40 grand a year *that includes* commission (and I'm achieving this) or go for this short lived contract but still establish myself with Publicis for future contracts. I hate this kind of choice...
What would you do?
 






Anonymous said:
so leave a job that pays 40 grand a year *that includes* commission (and I'm achieving this) or go for this short lived contract but still establish myself with Publicis for future contracts. I hate this kind of choice...
What would you do?
Click to expand...

Honestly??? Stay where you are. Publicis does not have any new contracts. The Crestor contract WILL end soon. I know that there are some people on the multiple product contract, that contract should last more than a year. Also, many Reps. (Very experienced) were sent home during training. Is it possible for you to double dip??? That would be the best option. Trust me, my team has not had a manager for a long time, it is easy to do! You will RARELY see your manager! Good Luck!!!!
 






Anonymous said:
Honestly??? Stay where you are. Publicis does not have any new contracts. The Crestor contract WILL end soon. I know that there are some people on the multiple product contract, that contract should last more than a year. Also, many Reps. (Very experienced) were sent home during training. Is it possible for you to double dip??? That would be the best option. Trust me, my team has not had a manager for a long time, it is easy to do! You will RARELY see your manager! Good Luck!!!!
Click to expand...

If the OCEAN Crestor contract is ending soon, why are the reps being given new target lists with increased head count? Many districts are showing New prescription growth for Crestor. The contract looks like it may have a good shot at being extended for another year post September.
 






bonus paid today, new targets coming by tomorrow...who knows what the future holds. I want to know what training session the person attended where 'many Reps. (Very experienced) were sent home during training' ??? Sounds silly
 






September is the time they will reorg like they did last year. This is why they said September contract will end. However, This does not mean we will be out of work. I have heard that we will be given Seroquel XR.
 






Anonymous said:
September is the time they will reorg like they did last year. This is why they said September contract will end. However, This does not mean we will be out of work. I have heard that we will be given Seroquel XR.
Click to expand...

OCEAN may get Nexium,too, I heard. If new scripts are generated for Crestor, the contact will be renewed.
 












Anonymous said:
Honestly??? Stay where you are. Publicis does not have any new contracts. The Crestor contract WILL end soon. I know that there are some people on the multiple product contract, that contract should last more than a year. Also, many Reps. (Very experienced) were sent home during training. Is it possible for you to double dip??? That would be the best option. Trust me, my team has not had a manager for a long time, it is easy to do! You will RARELY see your manager! Good Luck!!!!
Click to expand...

I actually MAY do this?
 






Anonymous said:
If the OCEAN Crestor contract is ending soon, why are the reps being given new target lists with increased head count? Many districts are showing New prescription growth for Crestor. The contract looks like it may have a good shot at being extended for another year post September.
Click to expand...

I agree. Crestor is by far the most critical product AZ has. Even with many managed care issues and generic encroachment, Crestor still has a firm place even if the docs can't write it first before using a generic atorvastatin. AZ will likely downsize more primary care reps and go more with contracts like Ocean. AZ gets a bargain with tons of pharma experience in Ocean and paying them a lot less than what the AZ regular reps are paid. I look for Ocean/Crestor to be around past the 1 year point.
 






Anonymous said:
I agree. Crestor is by far the most critical product AZ has. Even with many managed care issues and generic encroachment, Crestor still has a firm place even if the docs can't write it first before using a generic atorvastatin. AZ will likely downsize more primary care reps and go more with contracts like Ocean. AZ gets a bargain with tons of pharma experience in Ocean and paying them a lot less than what the AZ regular reps are paid. I look for Ocean/Crestor to be around past the 1 year point.
Click to expand...

I agree.
 












Anonymous said:
The contract with AZ should be extended if new prescrptions are significantly increased. More and more districts are showing positive trends.
Click to expand...

February 28, 2012 (Silver Spring, Maryland) — Taking a statin can raise blood sugar and glycosylated hemoglobin HbA1c levels, according to a new labeling change approved by the Food and Drug Administration (FDA) today for the entire drug class [1].

As reported by heartwire , recent studies of popular statins showed a significant increase in the risk of diabetes mellitus associated with high-dose statin therapy. The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial showed a 27% increase in diabetes mellitus in patients taking rosuvastatin compared to placebo. Also, the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis In Myocardial Infarction 22 (PROVE-IT TIMI 22) substudy showed that high-dose atorvastatin can worsen glycemic control.

The labeling changes approved by the FDA also include new information on the potential for usually minor and reversible cognitive side effects. Also, the label for lovastatin has been significantly updated to provide information on contraindications and dose limitations for the drug in patients taking other medicines that may increase the risk for muscle injury.

The FDA says it is also eliminating the recommendation that patients on statins undergo routine periodic monitoring of liver enzymes, because this approach is ineffective in detecting and preventing the "rare and unpredictable" serious liver injuries related to statins. Statin therapy should be interrupted if the patient shows signs of serious liver injury, hyperbilirubinemia, or jaundice. The statin therapy should not be restarted if the drugs cannot be ruled out as a cause of the problems, the labeling will now state.


WE MAY BE DISCUSSING LABEL CHANGES!!!
 






Anonymous said:
February 28, 2012 (Silver Spring, Maryland) — Taking a statin can raise blood sugar and glycosylated hemoglobin HbA1c levels, according to a new labeling change approved by the Food and Drug Administration (FDA) today for the entire drug class [1].

As reported by heartwire , recent studies of popular statins showed a significant increase in the risk of diabetes mellitus associated with high-dose statin therapy. The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial showed a 27% increase in diabetes mellitus in patients taking rosuvastatin compared to placebo. Also, the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis In Myocardial Infarction 22 (PROVE-IT TIMI 22) substudy showed that high-dose atorvastatin can worsen glycemic control.

The labeling changes approved by the FDA also include new information on the potential for usually minor and reversible cognitive side effects. Also, the label for lovastatin has been significantly updated to provide information on contraindications and dose limitations for the drug in patients taking other medicines that may increase the risk for muscle injury.

The FDA says it is also eliminating the recommendation that patients on statins undergo routine periodic monitoring of liver enzymes, because this approach is ineffective in detecting and preventing the "rare and unpredictable" serious liver injuries related to statins. Statin therapy should be interrupted if the patient shows signs of serious liver injury, hyperbilirubinemia, or jaundice. The statin therapy should not be restarted if the drugs cannot be ruled out as a cause of the problems, the labeling will now state.


WE MAY BE DISCUSSING LABEL CHANGES!!!
Click to expand...

I Don't think so. AZ is discussing possible Merger, that would make all Contracts Null and Void, that means we are gone!
 
























Anonymous said:
If a merger happens we will be done for sure
Click to expand...

If a merger happens with BMS or another company, it will take considerable time before finalization-hurdles to clear with FTC, etc. In the meantime, this contract runs through September, and AZ does need Ocean reps to sell Crestor. They are a lot less expensive than the full time AZ MCL-MCR reps in the PC sales force.
 






Anonymous said:
If a merger happens with BMS or another company, it will take considerable time before finalization-hurdles to clear with FTC, etc. In the meantime, this contract runs through September, and AZ does need Ocean reps to sell Crestor. They are a lot less expensive than the full time AZ MCL-MCR reps in the PC sales force.
Click to expand...

AZ will likely have another layoff and Ocean reps will replace them.
 






Top Bottom
Back
Quote